Andrew J. Piper-Vallillo and Lecia V. Sequist
JACC Journals › JACC: CardioOnc › Archives › Vol. 1 No. 2
CARDIONCOLOGY.ORG ABSTRACT:
This Editorial Comment addresses the concerns associated with the risk of osimertinib cardiac toxicity.
The authors argue that the observed risks do not warrant changes to the prescription of osimertinib. Rather, they recommend that the best way forward for now is to increase awareness of osimertinib-induced cardiotoxicity and include it as part of the differential for patients experiencing specific symptoms along with the development of a best approach for testing and monitoring to identify serious toxicities early enough to intervene.
Go to cardioncology.org list of contents of this JACC CardioOncology issue
© All Rights Reserved